Marinus pharmaceuticals inc (MRNS)
Balance Sheet / Yearly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Dec'13
ASSETS
Current assets:
Cash and cash equivalents

70,326

90,943

37,159

49,436

60,848

67,727

19,662

21,467

27,181

33,531

37,530

19,531

22,576

26,178

32,895

39,102

46,729

51,722

28,027

38,933

44,477

49,720

47,105

8,415

10,037

Short-term investments

7,460

739

2,730

2,481

-

4,998

19,967

24,902

24,839

19,861

5,435

744

2,184

3,922

3,675

4,917

4,471

4,474

4,974

995

995

-

-

-

-

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

932

-

Prepaid expenses and other current assets

2,212

2,452

1,252

2,276

2,024

1,215

1,188

1,038

1,698

978

582

684

916

199

553

385

516

1,571

1,859

207

322

428

439

100

1,762

Total current assets

79,998

94,134

41,141

54,193

62,872

73,940

40,817

47,407

53,718

54,370

43,547

20,959

25,676

30,299

37,123

44,404

51,716

57,767

34,860

40,135

45,794

50,148

47,544

9,448

11,799

Property and equipment, net

2,186

2,265

2,337

2,381

2,216

1,294

1,282

1,280

1,315

1,338

1,172

1,136

1,148

1,148

1,016

1,017

779

31

36

39

42

44

8

11

16

Investments

-

-

-

-

-

-

-

-

-

4,964

19,938

-

-

-

496

744

248

1,488

1,489

496

496

-

-

-

-

Other assets

2,374

2,443

2,322

2,391

2,531

-

-

-

-

-

-

-

-

-

-

-

43

362

368

370

19

21

8

19

9

Total assets

84,558

98,842

45,800

58,965

67,619

75,234

42,099

48,687

55,033

60,672

64,657

22,095

26,824

31,447

38,635

46,165

52,786

59,648

36,753

41,040

46,351

50,213

47,560

9,478

11,824

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Current portion of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,500

3,627

2,878

2,128

3,127

1,750

875

-

-

-

-

Accounts payable

2,845

2,763

3,561

4,973

1,932

2,472

2,917

1,294

797

927

634

1,161

2,236

2,809

3,845

2,824

2,553

3,146

2,300

1,097

3,055

536

827

1,742

78

Accrued expenses

7,479

5,268

5,010

4,231

4,745

4,437

3,960

2,266

997

1,617

1,796

1,016

833

1,775

1,836

3,745

2,323

2,161

1,236

3,000

1,516

1,503

508

466

1,096

Current portion of notes payable

-

-

-

-

-

-

-

-

-

-

-

3,497

3,500

3,500

-

-

-

-

-

-

-

-

-

-

-

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

794

1,192

Total current liabilities

10,325

8,031

8,571

9,204

6,677

6,909

6,877

3,560

1,794

2,544

2,430

5,674

6,569

8,084

9,181

10,196

7,754

7,435

6,663

5,847

5,446

2,039

1,335

3,003

2,366

Notes payable

-

-

-

-

-

-

-

-

-

-

-

-

870

1,743

2,616

3,489

4,363

5,236

4,375

5,250

6,125

7,000

2,000

2,000

-

Other long-term liabilities

2,921

3,042

3,158

3,176

3,197

-

100

107

114

120

127

132

137

141

145

149

102

56

57

59

50

20

-

-

-

Total liabilities

13,245

11,073

11,729

12,380

9,874

6,909

6,977

3,667

1,908

2,664

2,557

5,806

7,576

9,968

11,942

13,834

12,219

12,727

11,095

11,156

11,621

9,059

3,335

5,003

2,366

Series A convertible preferred stock, $0.001 par value; 25,000,000 shares authorized, 30,000 shares issued and outstanding at March 31, 2020 and December 31, 2019

28,200

28,200

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Commitments and contingencies (Note 9)

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

0

-

-

0

Stockholders’ equity:
Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

0

-

0

Common stock, $0.001 par value; 100,000,000 shares authorized, 86,761,236 issued and 86,732,035 outstanding at March 31, 2020 and 86,500,353 issued and 86,471,122 outstanding at December 31, 2019

87

87

53

53

53

53

41

41

41

41

40

23

22

20

20

20

20

19

14

14

14

14

13

0

1

Additional paid-in capital

306,124

295,056

254,182

252,891

251,628

249,727

206,450

205,279

203,917

202,790

202,067

152,085

150,493

147,288

146,487

145,662

144,949

144,088

115,217

114,481

114,059

113,476

112,940

1,195

1,121

Treasury stock at cost, 29,231 shares at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

-

0

-

-

-

0

0

0

0

Accumulated other comprehensive income

28

-

1

-

-

-2

-28

-69

-107

-96

-18

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accumulated deficit

-263,100

-235,574

-220,200

-206,400

-193,900

-181,453

-171,341

-160,231

-150,726

-144,727

-139,989

-135,819

-131,267

-125,829

-119,814

-113,351

-104,402

-97,186

-89,573

-84,611

-79,343

-72,336

-68,729

-67,060

-61,503

Total stockholders’ equity

43,113

59,569

34,071

46,585

57,745

68,325

35,122

45,020

53,125

58,008

62,100

16,289

19,248

21,479

26,693

32,331

40,567

46,921

25,658

29,884

34,730

41,154

44,225

-65,864

-60,381

Total liabilities and stockholders’ equity

84,558

98,842

45,800

58,965

67,619

75,234

42,099

48,687

55,033

60,672

64,657

22,095

26,824

31,447

38,635

46,165

52,786

59,648

36,753

41,040

46,351

50,213

47,560

9,478

11,824